Motus GI Holdings, Inc. (MOTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
MOTS POWR Grades
- Growth is the dimension where MOTS ranks best; there it ranks ahead of 87.68% of US stocks.
- The strongest trend for MOTS is in Stability, which has been heading down over the past 31 weeks.
- MOTS ranks lowest in Quality; there it ranks in the 2nd percentile.
MOTS Stock Summary
- MOTS has a market capitalization of $42,709,253 -- more than approximately only 7.47% of US stocks.
- MOTS's price/sales ratio is 352.97; that's higher than the P/S ratio of 98.3% of US stocks.
- Motus GI Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -49.47%, greater than the shareholder yield of just 5.52% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Motus GI Holdings Inc, a group of peers worth examining would be XAIR, MDGS, ACRS, APTX, and CUE.
- MOTS's SEC filings can be seen here. And to visit Motus GI Holdings Inc's official web site, go to www.motusgi.com.
MOTS Valuation Summary
- In comparison to the median Healthcare stock, MOTS's price/earnings ratio is 105.59% lower, now standing at -1.9.
- MOTS's price/sales ratio has moved NA NA over the prior 42 months.
- MOTS's price/earnings ratio has moved up 3.3 over the prior 42 months.
Below are key valuation metrics over time for MOTS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MOTS | 2021-07-20 | 362.8 | 2.3 | -1.9 | -1.4 |
| MOTS | 2021-05-03 | 591.8 | 5.1 | -3.0 | -2.4 |
| MOTS | 2020-10-14 | 209.9 | 3.1 | -1.2 | -0.9 |
| MOTS | 2019-10-31 | 16600.0 | 6.2 | -2.2 | -1.9 |
| MOTS | 2018-08-29 | 2946.4 | 6.1 | -4.5 | -4.2 |
| MOTS | 2018-08-03 | 13785.7 | 5.6 | -7.3 | -6.0 |
MOTS Price Target
For more insight on analysts targets of MOTS, see our MOTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.24 | Average Broker Recommendation | 1.25 (Strong Buy) |
MOTS Stock Price Chart Interactive Chart >
MOTS Price/Volume Stats
| Current price | $0.96 | 52-week high | $2.74 |
| Prev. close | $0.90 | 52-week low | $0.68 |
| Day low | $0.88 | Volume | 429,466 |
| Day high | $0.96 | Avg. volume | 3,206,981 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $1.13 | Market Cap | 44.91M |
Motus GI Holdings, Inc. (MOTS) Company Bio
Motus GI Holdings, Inc., a development stage company, engages in developing single-use medical device systems in the United States. It is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The company is based in Tirat Carmel, Israel.
Latest MOTS News From Around the Web
Below are the latest news stories about Motus GI Holdings Inc that investors may wish to consider to help them evaluate MOTS as an investment opportunity.
Motus GI Secures Expanded $12M Credit Financing to Support Growth StrategyFORT LAUDERDALE, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has successfully refinanced its debt and expanded its long-term credit facility by securing a new loan agreement with Kreos Capital VI LP (Kreos Capi |
Is Motus GI Holdings, Inc. (MOTS) A Good Stock To Buy?No summary available. |
Motus GI to Present at the Ladenburg Thalmann Healthcare ConferenceFORT LAUDERDALE, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (Motus GI or the Company), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to present at the upcoming Ladenburg Thalmann Healthcare Conference begin held from July 13 to July 14. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning! |
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit CommitteeFORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Companys Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (Nasdaq: NK) and Immunity Bio, Inc. (Nasdaq: IBRX). |
MOTS Price Returns
| 1-mo | -7.69% |
| 3-mo | -30.94% |
| 6-mo | -33.33% |
| 1-year | -23.20% |
| 3-year | -85.78% |
| 5-year | N/A |
| YTD | 1.27% |
| 2020 | -58.60% |
| 2019 | -26.37% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching MOTS
Want to see what other sources are saying about Motus GI Holdings Inc's financials and stock price? Try the links below:Motus GI Holdings Inc (MOTS) Stock Price | Nasdaq
Motus GI Holdings Inc (MOTS) Stock Quote, History and News - Yahoo Finance
Motus GI Holdings Inc (MOTS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...